MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients

Ariel Koren, Carina Levin, Leonid Livshits, Fabio Valeri, Sari Peretz, Sivan Raz, Anna Yu Bogdanova, Max Gassmann

Open source

DOI
10.1002/hem3.70278
Published
2026-01
Container
HemaSphere
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/hem3.70278,
  title = {MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients},
  author = {Ariel Koren and Carina Levin and Leonid Livshits and Fabio Valeri and Sari Peretz and Sivan Raz and Anna Yu Bogdanova and Max Gassmann},
  year = {2026},
  journal = {HemaSphere},
  doi = {10.1002/hem3.70278},
  url = {https://doi.org/10.1002/hem3.70278}
}

RIS

TY  - JOUR
TI  - MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients
AU  - Ariel Koren
AU  - Carina Levin
AU  - Leonid Livshits
AU  - Fabio Valeri
AU  - Sari Peretz
AU  - Sivan Raz
AU  - Anna Yu Bogdanova
AU  - Max Gassmann
PY  - 2026
JO  - HemaSphere
DO  - 10.1002/hem3.70278
UR  - https://doi.org/10.1002/hem3.70278
ER  - 

APA

Koren, A., Levin, C., Livshits, L., Valeri, F., Peretz, S., Raz, S., Bogdanova, A. Y., & Gassmann, M. (2026). MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients. HemaSphere. https://doi.org/10.1002/hem3.70278

Source records